Sodium-glucose cotransporter 2 inhibitors (SGLT2i), including empagliflozin, dapagliflozin, and canagliflozin, have emerged as a promising class of medications with some antihypertensive effects, in addition to their established benefits in type 2 diabetes mellitus (T2DM) and HF (58–60). This evidence concerns the gene SLC5A2 and hydrops fetalis.